Aimin Li

机构：Hebei Medical University, City Of Hope National Medical Center, Dalian University of Technology, Dalian University, Second Hospital of Hebei Medical University, Xingtai People's Hospital, The First People’s Hospital of Lianyungang · ORCID：0000-0001-9459-5540

发表论文 344 篇 · 总被引 6706 次 · h-index 44

代表论文

• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate (2025 · Antioxidants · 被引 7)
• Inhibiting Arginine Metabolism via ALDH2/ARG2 Axis Blockade Potentiates Immune Checkpoint Inhibitors in Colorectal Cancer (2025 · Molecular Cancer Therapeutics · 被引 4)
• FUT3 mediated GRP78 fucosylation promotes colorectal cancer survival and proliferation under glucose restriction via PERK/ATF4/STC2 axis (2025 · npj Precision Oncology · 被引 3)
• Dual-driven optimization of collaborative multi-agent via case learning and curiosity (2025 · Neural Networks · 被引 2)
• Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial (2025 · Surgical Endoscopy · 被引 1)